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Self‑rated health in individuals 
with and without disease 
is associated with multiple 
biomarkers representing multiple 
biological domains
L. Kananen1,2,3, L. Enroth1,2, J. Raitanen1,2, J. Jylhävä2,4, A. Bürkle5, M. Moreno‑Villanueva5, 
J. Bernhardt6, O. Toussaint7,32, B. Grubeck‑Loebenstein8, M. Malavolta9, A. Basso9, 
F. Piacenza9, S. Collino10, E. S. Gonos11, E. Sikora12, D. Gradinaru13, E. H. J. M. Jansen14, 
M. E. T. Dollé14, M. Salmon15, W. Stuetz16, D. Weber17, T. Grune17,18,19, N. Breusing19, 
A. Simm20, M. Capri21, C. Franceschi21,22, P. E. Slagboom23, D. C. S. Talbot24, C. Libert25,26, 
S. Koskinen27, H. Bruunsgaard28, ÅM. Hansen29,30, R. Lund29,31, M. Hurme2,3 & M. Jylhä1,2* 
Self‑rated health (SRH) is one of the most frequently used indicators in health and social research. 
Its robust association with mortality in very different populations implies that it is a comprehensive 
measure of health status and may even reflect the condition of the human organism beyond clinical 
diagnoses. Yet the biological basis of SRH is poorly understood. We used data from three independent 
European population samples (N approx. 15,000) to investigate the associations of SRH with 150 
biomolecules in blood or urine (biomarkers). Altogether 57 biomarkers representing different organ 
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systems were associated with SRH. In almost half of the cases the association was independent 
of disease and physical functioning. Biomarkers weakened but did not remove the association 
between SRH and mortality. We propose three potential pathways through which biomarkers may 
be incorporated into an individual’s subjective health assessment, including (1) their role in clinical 
diseases; (2) their association with health‑related lifestyles; and (3) their potential to stimulate 
physical sensations through interoceptive mechanisms. Our findings indicate that SRH has a solid 
biological basis and it is a valid but non‑specific indicator of the biological condition of the human 
organism.
Self-rated health (SRH) is one of the most frequently used measures in epidemiological, clinical and social 
research. It is known to predict mortality, future functional status and outcome of treatment in populations that 
vary by age, gender, social class, health status, country and  culture1,2. In many studies SRH remains a signifi-
cant predictor of mortality after adjustment for several other health  indicators2. However, the wider the array 
of objectively measured health variables, the weaker is the independent predictive power of  SRH3,4. Therefore 
it is plausible that the association between SRH and mortality is not causal but is due to the ability of the self-
assessment to more exhaustively capture the realm of `health` and the objective bodily condition than most 
other health  indicators2,5.
Jylhä (2009) has suggested that when asked to evaluate their general health status, respondents will take into 
account any individual relevant information that they think describes their “health”. This information is then 
considered in the context of the social and psychological situation. Empirical studies show that individuals 
will mainly take into account their medical diagnoses and functional  status1, but also experienced symptoms, 
medication and other signs of health problems, and particularly in the absence of any evident health problems, 
different health-related lifestyles and risk  factors6.
A number of studies have found associations between SRH and biomarker levels (i.e. quantities of biomol-
ecules) in blood, such as white cell count, albumin and  haemoglobin3, HDL  cholesterol3,7–9,  leptin10, TNF-α and 
IL-1ra11,  CD19+ cells and  IgG12,  CRP13–15, IL-613,16,17, fasting plasma glucose and glycosylated  haemoglobin18 
and vitamin  D19,20. The findings are fragmented, however, as each study usually addresses only a few indicators. 
Furthermore, most samples have been small, and in many cases other health data have been less than optimal. 
At least in part, these associations probably reflect the severity and symptoms of chronic diseases. Yet it is pos-
sible to hypothesize that the level of and changes in some biomarkers may, through interoceptive processes, be 
associated with sensations and symptoms that individuals take into account in their self-ratings of health. Overall, 
little is known about the experiential counterparts of variations in blood biochemistry, although the connections 
of fatigue with peripheral inflammation for example, are well  described21,22.
In order to understand the potential of SRH as a measure of health in clinical practice and research, it is 
important to know how accurately SRH reflects the condition of the human body. In the present explorative study, 
we investigated the associations of SRH with a wide array of biomolecule levels measured in blood and urine. 
These biomarkers provide more detailed information about the condition of the human body than diagnostic 
names alone as they can reflect the stage and severity of current pathologies as well as the physiological processes 
taking place in individuals without clinical diagnoses. We hypothesize that the possible association between 
SRH and biomarkers is largely, but not entirely, explained by diseases and physical functioning, which at least 
to some extent reflects the severity of diseases. We also hypothesize that the association of SRH and mortality is 
partly explained by the measured biomarkers. We addressed the following questions: (i) to what extent are the 
biomarkers available in the study associated with SRH; (ii) to what extent are the associations between biomarkers 
and SRH explained by disease diagnoses and physical functioning; and (iii) do the biomarkers associated with 
SRH explain part of the association between SRH and mortality? Analyses i) and iii) were also performed for 
individuals without diagnosed diseases. We used three extensive population-based data sets: MARK-AGE, the 
Copenhagen Aging and Midlife Biobank (CAMB), and Health 2000, covering a total of approx. 15,000 individu-
als and 150 biomarkers.
Results
Participant characteristics. In MARK-AGE (n = 3,187) 12% rated their health as excellent, 35% as very 
good, 41% as good, 11% as fair and 1.4% as poor. In CAMB (n = 5,335) the figures were 9.1%, 41%, 40%, 8.6% 
and 1.4%, respectively. In Health 2000 (n = 6,444) 32% rated their health as good, 30% as rather good, 27% as 
moderate, 8% as rather poor and 3.5% as poor. Table 1 shows the participants’ characteristics by SRH. In all three 
data sets poorer SRH was associated with a higher number of diseases and poorer physical functioning (Table 1; 
Chi-square test: p < 0.001).
Biomarkers associated with SRH. Out of the 150 biomarkers investigated (Fig.  1A, Supplementary 
information 1, Supplementary information 2: Table S1 and S2), 57 were significantly associated with SRH in 
linear regression analyses that were adjusted for age and gender (model i). Table 1 shows the means and medians 
by SRH for these 57 biomarkers. Eleven of them were available in two or three data sets (Table 2, Supplementary 
information 2: Table S1 and S2) and they showed similar directions of associations across the data sets. Of the 57 
biomarkers, 46 were available for analysis in one data set only (Table 3, Supplementary information 2: Table S1 
and S2).
When additionally adjusted for number of diseases and physical functioning (model ii), 26 biomarkers were 
still associated with SRH. Seven of these biomarkers were available in two or three data sets (Table 2) and 19 
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Self-rated health
MARK-AGE CAMB Health 2000
’good’, ’very good’ or 
’excellent’ ‘poor’ or ‘fair’
’good’, ’very good’ or 
’excellent’ ‘poor’ or ‘fair’
’moderate’, ’rather 
good’ or ’good’ ‘poor’ or ‘rather poor’
Sample size
% (N) 88 (2798) 12 (389) 90 (4799) 10 (536) 88 (5679) 12 (765)
Age
Min–Max, years 18–92 35–78 48–62 49–62 30–99 30–97
Mean (Median), years 57 (59) 62 (64) 54 (56) 54 (56) 52 (49) 65 (67)
Male
% (N) 88 (1338) 12 (177) 90 (3296) 10 (363) 88 (2554) 12 (349)
Female
% (N) 87 (1460) 13 (212) 90 (1503) 10 (173) 88 (3125) 12 (416)
Number of diseases
No diseases, % (N) 95 (1572) 5 (85) 97 (2418) 3 (81) 97 (2489) 3 (85)
One disease, % (N) 87 (856) 13 (131) 90 (1699) 10 (195) 92 (1777) 8 (163)
Two diseases, % (N) 73 (280) 28 (106) 79 (564) 21 (153) 79 (882) 21 (232)
Three diseases, % (N) 62 (83) 39 (52) 58 (102) 42 (74) 71 (397) 29 (160)
4 + diseases, % (N) 32 (7) 68 (15) 33 (16) 67 (33) 52 (134) 48 (125)
Difficulties in physical functioning, sum of scores
0, % (N) 98 (485) 2 (10) 98 (1386) 2.2 (31) 97 (1766) 3 (64)
1 or 2, % (N) 92 (1584) 8 (137) 93 (2915) 7 (210) 95 (2907) 5 (159)
3 or 4, % (N) 78 (687) 22 (193) 67 (474) 33 (229) 76 (259) 24 (237)








ferase, U/l 24 (22) 26 (24) – – – –
Calcium status Calcium, mmol/l – – – – 2.4 (2.4) 2.4 (2.4)
Endocrine function Leptin, ng/l – – – – 17 (11) 22 (15)
Glucose metabolism
Glucose, mmol/l 5.2 (5.1) 5.7 (5.3) 5.5 (5.3) 5.9 (5.4) 5.5 (5.3) 6.0 (5.5)
Haemoglobin A1C, % 6.0 (5.9) 6.3 (6.1) 5.3 (5.3) 5.5 (5.5) 5.3 (5.2) 5.7 (5.4)
Insulin, mU/ml 6.1 (5) 8.5 (5.7) – – 9.1 (7.0) 13 (9.0)
Immune system
CRP, mg/l 2.1 (1.2) 3.4 (1.8) 2.2 (1.1) 3.9 (1.9) 2.0 (0.7) 4.0 (1.4)
CMV antibodies, U/l 39 (22) 53 (37) – – – –
Tetanus IgG antibod-
ies, IU/ml 3.7 (1.6) 2.6 (0.78) – – – –
Rheumatoid factor, 











Apolipoprotein-A1, g/l – – – – 1.6 (1.6) 1.6 (1.5)
Apolipoprotein-B, g/l – – – – 1.2 (1.2) 1.3 (1.3)
Clusterin (ApoJClu; 
Apolipoprotein J/
Clusterin in serum), 
µg/ml
70 (68) 75 (74) – – – –
HDL:Total cholesterol, 
ratio, % 28 (27) 27 (26) 25 (24) 24 (23) 23 (22) 22 (20)
HDL1 (large particles) 
Cholesterol, mg/dl 30 (27) 29 (26) – – – –
HDL2 (small particles) 
Cholesterol, mg/dl 38 (38) 37 (36) – – – –
HDL2 (small particles) 
Triglycerides, mg/dl 5.2 (5.0) 5.8 (5.7) – – – –
HDL Cholesterol, 
mol/l ELISA 1.5 (1.5) 1.4 (1.4) 1.5 (1.5) 1.4 (1.3) 1.3 (1.3) 1.3 (1.2)
HDL Cholesterol, mg/
dl NMR 72 (70) 70 (67) – – – –
HDL Triglycerides, 
mg/dl 8.0 (7.6) 9.1 (8.9) – – – –
LDL1 (large particles) 
Cholesterol, mg/dl 59 (58) 50 (50) – – – –
LDL2 (small particles) 
Triglycerides, mg/dl 7.1 (6.3) 7.9 (6.96) – – – –
LDL Cholesterol, 
mmol/l ELISA 3.3 (3.3) 3.2 (3.2) 3.0 (3.0) 2.9 (2.9) 3.7 (3.6) 3.7 (3.7)
LDL Cholesterol, mg/
dl MARK-AGE, NMR 130 (130) 120 (120) – – – –
Triglycerides, mg/dl 
MARK-AGE, NMR mmol/l 
H2000 & CAMB, ELISA
















12 (11) 14 (12) – – – –
VLDL Cholesterol, 
mg/dl 26 (22) 30 (25) – – – –
VLDL Triglycerides, 




lite, in urine, mM/L/
mM creatinine
7.3 (6.7) 8.3 (7.3) – – – –
Marker of tissue 
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biomarkers in one data set only (Table 3). A schema of the analysis pipeline and summaries of the findings are 
shown in Supplementary information 2 (Figure S1, Table S1 and S2) and Fig. 1B.
As examples of replicated and new findings representing different biological domains, Fig. 2 shows the asso-
ciations of eight selected biomarkers, categorized as quartiles, with SRH. Most of these analyses showed a graded 
association of poorer SRH with poorer biomarker levels.
Mortality analysis. In the Health 2000 data the association between SRH and mortality (iii) was analysed 
using Cox regression analysis. Out of 5,957 participants with a full set of data for relevant variables, 1,207 (20%) 







nmol/l 52 (49) 44 (41) – – 45 (43) 42 (41)
Alpha-carotene, 
µmol/l 0.19 (0.14) 0.16 (0.11) – – – –
Beta-carotene, µmol/l 0.69 (0.57) 0.50 (0.42) – – – –
Beta-cryptoxanthin, 
µmol/l 0.31 (0.22) 0.22 (0.15) – – – –
Hippurate in urine, 
area (a.u.) 15 (12) 13 (10) – – – –
Lutein, µmol/l 0.29 (0.27) 0.24 (0.2) – – – –
Normed concentration 
of vitamin C, pmol/
µg DNA
2400 (2100) 2300 (2000) – – – –
Retinol in serum, 
µmol/l 1.8 (1.7) 1.7 (1.7) – – – –
Trigonelline in urine, 
area (a.u.) 1.3 (1.0) 1.2 (0.74) – – – –









urine, area (a.u.) 10.7 (8.9) 9.4 (7.2) – – – –
One-carbon metabo-
lism; CV health Homocysteine, µmol/l 15 (14) 16 (15) – – 12 (11) 15 (13)
Oxidative stress Protein carbonyls, nmol/mg 0.58 (0.58) 0.59 (0.59) – – – –
Protein modification
N-glycosylation status 
of serum proteins, %, 
peak 9
2.5 (2.4) 2.7 (2.6) – – – –
N-glycosylation status 
of urinary proteins, %, 
peak 6
3.0 (3.0) 3.4 (3.2) – – – –
N-glycosylation status 
of serum proteins, %, 
peak 3
7.2 (7.0) 6.9 (6.7) – – – –
Purine metabolism; 
anionic form of uric 
acid
Urate, µmol/l – – – – 300 (290) 330 (320)
Selenium metabolism
Selenium in plasma, 
ppb 110 (110) 110 (110) – – – –
Plasma Selenium 
bound to Albumin or 
Selenoprotein P, ppb
91 (89) 85 (83) – – – –
Plasma Selenium 
bound to Glutathione 
Peroxidase, ppb
23 (22) 23 (22) – – – –
Smoking exposure Cotinine, µg/l – – – – 120 (10) 130 (9)
Tissue repair Fibrinogen, mg/ml 3.6 (3.4) 4.0 (3.8) – – – –
Renal function Albumin in urine, mg/l – – – – 14 (3.1) 45 (4.3)
Table 1.  Participant characteristics by SRH. The 57 biomarkers presented in the table were all 
associated with SRH in linear modelling when adjusted for age and gender (model i). a.u. arbitrary unit, 
CMV  cytomegalovirus, CRP  C-reactive protein, CV  cardiovascular, ELISA  enzyme-linked immunosorbent 
assay, HDL  high-density lipoprotein, IU  international unit, IL  interleukin, LDL  low-density lipoprotein, 
NMR  nuclear magnetic resonance, OH  hydroxyl, ppb  parts per billion, VLDL  very low-density lipoprotein.
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A graded relationship was found between SRH and mortality in models adjusting for age and gender, and 
then additionally for diseases (Fig. 3). In the third model the analysis was further adjusted for ten biomarkers 
that were significantly associated with SRH (model ii, results shown in Tables 2 and 3: leptin, apolipoprotein B, 
cotinine, HbA1C, HDL:total cholesterol ratio, HDL cholesterol, triglycerides, 25-hydroxy-vitaminD, gamma-
glutamyltransferase and CRP). The association between SRH and mortality was weakened after the addition of 
these biomarkers to the model, but it still remained significant: hazard ratios (95% CIs) 1.1 (0.9, 1.4), 1.3 (1.0, 
1.5) and 2.0 (1.6, 2.5), respectively.
Analyses for individuals without diseases. All analyses were also conducted separately for subsamples 
of individuals who had no disease diagnoses (MARK-AGE n = 1657, CAMB n = 2499, Health 2000 n = 2574). 
Descriptive statistics for these participants are shown in Supplementary information 2: Table S3. In linear regres-
sion models adjusted for age and gender, 8 biomarkers that were available for analysis in two or three data sets 
(p < 0.05 in all data sets ) and 8 biomarkers that were available in one data set (Bonferroni-adjusted p value < 0.05) 
were significantly associated with SRH (Supplementary information 2: Table S1, S4 and S5). As in the results for 
the whole data, CRP, triglycerides and HDL cholesterol showed a significant association in all three data sets, 
and vitamin D in the two data sets where it was available. For the biomarkers that in the full data were signifi-
cantly associated with SRH, with only few exceptions, the direction of the associations was the same among the 
“healthy” participants, although the associations in the latter group did not always reach statistical significance. 
Results for all biomarkers from the analysis in healthy individuals are shown in Supplementary information 3.
For the subsample of individuals without diagnoses (n = 2,408) in the Health 2000 data, the association 
between SRH and mortality was analysed using Cox regression analysis. During the 15-year follow-up the 
number of deaths was 193 (8%), and average survival time for the deceased participants in this sample was 9.2 
(SD 4.0) years. In this subsample SRH was a significant dose-responsive predictor of mortality (Supplementary 
information 2: Figure S2). When the biomarkers that showed a significant association with SRH in the full data 
analysis (Table 2 and 3, model (ii) were included in the model, and when good SRH was set as the reference 
category, hazard ratios (95% CIs) for rather good, moderate and poor SHR were 1.2 (0.9, 1.7), 1.3 (0.9, 1.9) and 
2.3 (1.3, 3.8), respectively.
Figure 1.  A summary of (A) the number of biomarkers in the analysis in the three data sets and (B) biomarkers 
associated with SRH, adjusted for age and gender (Model i, in the full samples). Sample types are indicated 
with colors: red = blood, yellow = urine, and * symbol indicates that association was significant also after the 
adjustment for diseases and physical functioning (Model ii, in the full samples).
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Discussion
The underlying assumption of this work was that SRH is a more comprehensive and sensitive indicator of 
the condition of the human organism than medical diagnoses or measures of physical functioning alone. We 
hypothesized that if this was true, SRH should show an association with blood and urine biomarkers that reflect 
the physiological regulation of the organism. Therefore, we analysed 150 biomarkers from almost 15,000 par-
ticipants enrolled in three population-based studies. Altogether 57 biomarkers showed a significant association 
with SRH, and for 26 of them the association was upheld when the number of chronic diseases and physical 
functioning were taken into account. In subsamples of individuals without chronic diseases, 16 biomarkers were 
associated with SRH. These associations were almost exclusively in a logical direction, i.e. a “worse” biomarker 
level was associated with poorer SRH and vice versa. Moreover, biomarkers weakened the association between 
SRH and mortality.
We had no a priori hypothesis as to which biomarkers are important regarding SRH. In this explorative study 
we included all blood and urine measures that were available in the study samples. Our results confirm the pre-
vious evidence for most biomarkers that have been reported to be associated with SRH, and they additionally 
reveal a large number of new associations. These biomarkers are descriptive of various biological systems of the 
human body, including inflammation (e.g. CRP), lipid and glucose metabolisms (e.g. cholesterol and HbA1C), 
oxidative stress (e.g. protein carbonyls) and tissue damage (cell-free DNA), as well as of lifestyles and environ-
mental exposures (e.g. carotenoids, vitamin D, cotinine). Many of the biomarkers associated with SRH are also 
known to be biomarkers of  ageing23.
When selected biomarkers—CRP, HDL cholesterol, HbA1C, 25-hydroxyl-vitamin-D, zeaxanthin, apolipo-
protein-B, cell-free DNA and protein carbonyls—were picked up as examples and examined as quartiles, poorer 
biomarker levels were fairly constantly associated with higher odds for poorer SRH in all data sets (Fig. 2). 
CRP is a proinflammatory marker and known to be associated with  SRH13–15. A few studies have also reported 
an association between poorer SRH and lower HDL  cholesterol3,7–9 and higher  HbA1C18 levels. In our study 
lower vitamin D level was associated with poorer SRH in both data sets where it was available, and a similar, 
Table 2.  Associations between biomarkers and SRH in linear regression analysis, adjusted for (i) age and 
gender and (ii) additionally for number of diseases and physical functioning. CRP  C-reactive protein, 
CV cardiovascular, HDL high-density lipoprotein, IU international unit, IL interleukin, LDL low-density 
lipoprotein, OH  hydroxyl, UVB ultraviolet B light, VLDL  very low-density lipoprotein. This table presents 
the results for all biomarkers (n = 17) available in two or three data sets (MARK-AGE, CAMB, and/or Health 
2000). Criteria for significant association of a biomarker was p < 0.05 in all data sets where it was analysed. 
p-values less than 0.05 are shown in bold. Results for all biomarkers are shown in Supplementary information 
1.
Domain Biomarker
MARK-AGE CAMB Health 2000
βi pi








 + physical 
functioning and 
number of diseases
βii pii βii pii βii pii
Muscle metabolism; 
renal health
Creatinine − 0.0011 0.24 − 0.0012 0.15 – – – – − 0.00062 0.50 − 0.0016 0.046
Creatinine in urine 0.00091 0.75 0.0030 0.24 – – – – − 0.00079 0.74 0.00084 0.69
Glucose and lipid 
metabolism Adiponectin − 0.0058 0.012 − 0.0028 0.18 – – – – − 0.0016 0.53 − 0.00050 0.82
Glucose metabolism
Insulin 0.014  < 0.001 0.0059 0.003 – – – – 0.0011 0.007 0.00036 0.32
Glucose 0.089  < 0.001 0.043  < 0.001 0.047  < 0.001 0.0092 0.17 0.063  < 0.001 0.015 0.086
Haemoglobin 
A1C, % 0.18  < 0.001 0.080  < 0.001 0.21  < 0.001 0.072  < 0.001 0.18  < 0.001 0.075  < 0.001
Iron metabolism Ferritin 0.00025 0.18 0.00010 0.54 – – – – 0.00055  < 0.001 0.00041  < 0.001
Lipid metabolism
HDL:Total cho-
lesterol − 0.011  < 0.001 − 0.0080  < 0.001 − 0.0089  < 0.001 − 0.0068  < 0.001 − 0.0098  < 0.001 − 0.0069  < 0.001
HDL Cholesterol − 0.33  < 0.001 − 0.16  < 0.001 − 0.27  < 0.001 − 0.16  < 0.001 − 0.24  < 0.001 − 0.10 0.001
Cholesterol, total − 0.074  < 0.001 − 0.015 0.31 − 0.034  < 0.001 − 0.0045 0.60 − 0.015 0.17 0.023 0.018
LDL Cholesterol − 0.062  < 0.001 − 0.010 0.55 − 0.027 0.039 0.0080 0.49 − 0.029 0.014 0.017 0.11
Triglycerides 0.0020  < 0.001 0.0011  < 0.001 0.092  < 0.001 0.044  < 0.001 0.10  < 0.001 0.054  < 0.001
Nutrition; UVB 









Homocysteine 0.0070 0.008 0.0026 0.28 – – – – 0.018  < 0.001 0.0056 0.019
Immune system CRP 0.035  < 0.001 0.020  < 0.001 0.028  < 0.001 0.011  < 0.001 0.016  < 0.001 0.0053 0.004
Oxygen transfer Haemoglobin − 0.0052 0.30 − 0.0028 0.52 0.044 0.012 0.014 0.35 0.0011 0.27 0.0018 0.039
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Domain Biomarker Data set βi pi
 + physical functioning and 
number of diseases
βii pii
Selenium metabolism Selenium MARK-AGE − 0.00564 8.28 × 10–16 − 0.00433 9.24 × 10–12
Selenium metabolism Selenium bound to Albumin or Selenoprotein P MARK-AGE − 0.00645 5.84 × 10
–16 − 0.00490 1.15 × 10–11
Smoking exposure Cotinine Health 2000 0.000382 7.33 × 10–14 0.000294 1.41 × 10–10
Nutrition Lutein MARK-AGE − 0.663 2.12 × 10–12 − 0.526 5.88 × 10–10
Nutrition Beta-cryptoxanthin MARK-AGE − 0.421 7.01 × 10–14 − 0.308 1.27 × 10–09
Endocrine function Leptin Health 2000 0.00892 1.82 × 10–26 0.00375 1.11 × 10–06
Nutrition Beta-carotene MARK-AGE − 0.251 2.39 × 10–16 − 0.135 1.20 × 10–06
Lipid metabolism Apolipoprotein-B Health 2000 0.177 4.02 × 10–05 0.180 3.10 × 10–06
Lipid metabolism VLDL1 (large particles) Cholesterol MARK-AGE 0.0110 1.81 × 10
–12 0.00658 3.44 × 10–06
Nutrition Zeaxanthin MARK-AGE − 3.42 1.06 × 10–11 − 2.06 5.98 × 10–06
Lipid metabolism VLDL Triglycerides MARK-AGE 0.00242 3.65 × 10–13 0.00132 1.39 × 10–05
Lipid metabolism VLDL1 (large particles) Triglycerides MARK-AGE 0.00253 1.45 × 10
–12 0.00138 2.15 × 10–05
Lipid metabolism VLDL Cholesterol MARK-AGE 0.00686 2.93 × 10–11 0.00394 2.47 × 10–05
Lipid metabolism VLDL2 (small particles) Triglycerides MARK-AGE 0.0229 3.60 × 10
–13 0.0119 3.58 × 10–05
Protein modification N-glycosylation status of serum proteins, peak 9 MARK-AGE 0.0577 1.26 × 10
–05 0.0462 9.70 × 10–05
Tissue damage Cell-free DNA MARK-AGE 0.693 2.08 × 10–07 0.464 9.99 × 10–05
Lipid metabolism LDL1 (large particles) Cho-lesterol MARK-AGE − 0.00515 2.13 × 10
–15 − 0.00233 0.000108
Nutrition Retinol MARK-AGE − 0.145 8.15 × 10–05 − 0.126 0.000154
Immune system Cytomegalovirus antibodies MARK-AGE 0.00182 1.05 × 10–07 0.00113 0.000235
Purine metabolism Urate Health 2000 0.00129 5.02 × 10–14 0.000205 0.190
Lipid metabolism HDL2 (small particles) Tri-glycerides MARK-AGE 0.0570 3.16 × 10
–13 0.0240 0.000805
Lipid metabolism HDL Cholesterol, NMR MARK-AGE − 0.00561 8.12 × 10–09 − 0.00285 0.00125
Nutrition Trigonelline in urine MARK-AGE − 0.0913 8.78 × 10–09 − 0.0469 0.00112
Creatine metabolism Guanidinoacetate (3–97s) in urine MARK-AGE − 0.0139 2.39 × 10
–08 − 0.00604 0.00753
Nutrition Hippurate in urine MARK-AGE − 0.00894 2.61 × 10–08 − 0.00396 0.00663
Lipid metabolism LDL2 (small particles) Tri-glycerides MARK-AGE 0.0229 1.84 × 10
–07 0.0126 0.00148
Lipid metabolism HDL1 (large particles) Cho-lesterol MARK-AGE − 0.00592 3.45 × 10
–07 − 0.00283 0.00715
Lipid metabolism HDL2 (small particles) Cholesterol MARK-AGE − 0.0129 6.50 × 10
–07 − 0.00731 0.00174
Lipid metabolism LDL Cholesterol, NMR MARK-AGE − 0.00243 2.26 × 10–06 − 0.000635 0.176
Transporter protein Albumin in urine Health 2000 0.000491 5.83 × 10–06 0.0000643 0.512
Immune system Tetanus IgG antibodies MARK-AGE − 0.0132 6.35 × 10–06 − 0.00871 0.000904
Lipid metabolism VLDL2 (small particles) Cholesterol MARK-AGE 0.0171 6.59 × 10
–06 0.0103 0.00254
Aminoacid metabolism Alanineaminotransferase MARK-AGE 0.00685 7.76 × 10–06 0.00337 0.0149
Calcium status Calcium Health2000 0.652 1.21 × 10–05 0.210 0.118
Lipid metabolism HDL Triglycerides MARK-AGE 0.0169 1.32 × 10–05 0.00684 0.0504
Protein modification N-glycosylation status of serum proteins, peak 3 MARK-AGE − 0.0424 2.35 × 10
–05 − 0.0261 0.0039
Oxidative stress Proteincarbonyls MARK-AGE 0.704 2.94 × 10–05 0.537 0.0004
Nutrition Alpha-carotene MARK-AGE − 0.333 3.03 × 10–05 − 0.0743 0.304
Tissue repair and revasculari-
zation Fibrinogen MARK-AGE 0.0469 3.86 × 10
–05 0.0256 0.0125
Selenium metabolism Selenium bound to Glu-tathione Peroxidase MARK-AGE − 0.0117 4.82 × 10
–05 − 0.00891 0.000565
Lipid metabolism Apolipoprotein-A1 Health 2000 − 0.177 4.90 × 10–05 − 0.0469 0.231
Protein modification N-glycosylation status of urinary proteins, peak 6 MARK-AGE 0.0343 8.28 × 10
–05 0.0254 0.00119
Lipid metabolism Apolipoprotein J/Clusterin MARK-AGE 0.00310 9.39 × 10–05 0.00159 0.0264
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strong association was also seen among individuals without chronic conditions. Previous studies with smaller 
Domain Biomarker Data set βi pi
 + physical functioning and 
number of diseases
βii pii
Immune system Rheumatoid factor Health 2000 0.000820 0.000126 0.000447 0.0200
Nutrition Normed concentration of vitamin C MARK-AGE − 0.0000410 0.000169 − 0.0000231 0.0183
Table 3.  Associations between biomarkers and SRH in linear regression analysis, adjusted for (i) age and 
gender and (ii) additionally for number of diseases and physical functioning. CRP C-reactive protein, HDL 
high-density lipoprotein, LDL low-density lipoprotein, NMR nuclear magnetic resonance, VLDL very low-
density lipoprotein. The Table shows 46 biomarkers that were available for analysis in one data set only and 
were associated with SRH in Model (i). 19 of them were associated with SRH also in Model (ii). The results 
for all biomarkers are shown in Supplementary information 1. Statistical significance level was at Bonferroni-
adjusted p value of 0.05, and p values below this threshold are shown in bold.
Figure 2.  Associations of the eight selected biomarkers, categorized as quartiles, with poor self-rated health. 
Odds ratios (ORs) and 95% confidence intervals (CIs) are from the logistic regression models, adjusted for 
age and gender. The “best” biomarker quartile was used as reference category. (A–H): C-reactive protein 
(CRP), high-density lipoprotein (HDL) cholesterol, haemoglobin A1C (HBA1C), 25-hydroxyl-vitamin-D 
(25-OH-vitaminD), zeaxanthin, apolipoprotein-B (Apo-B), cell-free DNA (cf-DNA) and protein carbonyls, 
respectively. The biomarkers were selected as examples of replicated and new associations representing different 
biological domains.
Figure 3.  Association of self-rated health with mortality in the Health 2000 data (n = 5,957; deceased n = 1,207; 
15-year follow-up). In Cox proportional hazards models (iii) hazard ratios (HRs) and 95% CIs were adjusted for 
(1) age and gender; (2) then additionally for number of diseases; and then (3) additionally for 10 biomarkers.
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samples have likewise shown an association between vitamin D and  SRH19,20. Recent studies have connected 
low vitamin D concentration with multiple extra-skeletal processes such as cancer progression, coronary heart 
disease, depression and a range of immune  functions24–26. The mechanisms of these associations are not well 
known, but it has been suggested that low vitamin D level should be understood as a marker of ill health rather 
than a causal  factor27,28.
This is the first study to report associations between SRH and e.g. zeaxanthin, apolipoprotein-B, cell-free 
DNA and protein carbonyls. Zeaxanthin is a carotenoid pigment present in the eye and obtained from the diet 
(e.g. egg yolk and orange peppers)29. It has antioxidative properties and is suggested to have a protective role 
against eye diseases (especially age-related macular degeneration) as well as cardiovascular diseases and  cancer30. 
Apolipoprotein B is mostly known as the LDL carrier protein, and it is an important contributor to atheroscle-
rosis and cardiovascular  disease31. Circulating cell-free DNA is a marker of cellular death and tissue damage 
in many acute and chronic conditions (e.g. sepsis, trauma, aseptic inflammation, cardiovascular diseases and 
cancer)32–37. Elevated levels of protein carbonyls (i.e. plasma protein oxidation levels) are a marker of oxidative 
stress and observed in various pathologies such as Alzheimer’s disease, rheumatoid arthritis, diabetes, sepsis, 
renal dysfunction and respiratory  failure38.
We suggest that there are three main pathways through which biomarkers measured in blood or urine can 
affect SRH. First, several biomarkers are characteristics of clinical diagnoses. For certain biomarkers such as 
cholesterol or glucose levels the role is well-known as is their significance as risk factors of disease. Individuals 
who are asked to rate their own health may be inclined to interpret high values (if they know them) as signs of 
poorer health. Yet respondents may not necessarily consider their biomarker levels or even be aware of them 
when asked to assess their health, but instead consider their disease diagnoses, symptoms or decreased physical 
functioning caused by their diseases. In this case the association between biomarkers and SRH is indirect and 
mediated by the association of SRH with diseases known to the respondents. This hypothesis for disease pathway 
is supported by the finding that associations between biomarkers and SRH were more marked among individuals 
with disease than those without.
Second, it is known that particularly individuals without major health problems take account of health-related 
lifestyles and behavioural risk factors as components of  SRH6,39. In the present study better SRH was associated 
with higher levels of carotenoids (zeaxanthin, beta-carotene, lutein, beta-cryptoxanthin and beta-carotene) in 
plasma, and hippurate and trigonelline in urine. These molecules serve as markers of fruit and vegetable intake. 
Worse SRH was associated with higher cotinine and gamma-glutamyltransferase levels, which serve as markers 
for smoking exposure and alcohol consumption, respectively. Again it is plausible that the route from biomarkers 
to SRH is indirect, i.e. that respondents assess their health as good or poor not on the basis of their biomarker 
levels but rather particular health-related lifestyles that are considered healthy or unhealthy.
Third, an interesting but poorly understood mechanism is the possibility that a biomarker level or change 
in biomarker level in the body might stimulate physical sensations, and that these sensations are interpreted as 
information about the state of one’s health. This is not a novel hypothesis but was suggested by Stenback as early 
as 1964 and later by Kaplan and Camacho in 1983 as one potential explanation for the association between SRH 
and  mortality40,41. Since these studies, research has continued to accumulate about the interoceptive processes 
through which information on internal states of the body is communicated to the brain to enable the regula-
tion of vital inner processes and the maintenance of physiological  stability21,42–44.Most of the research data on 
interoceptive signalling of humoral processes, i.e. changes in blood substance levels, concerns inflammation: 
higher circulating levels of inflammatory biomarkers, cytokines, are known to underlie symptoms such as fatigue, 
general malaise, poor appetite and low  mood21,22, and they are known to be associated with poor  SRH45,46. In our 
study, higher levels of inflammatory markers such as CRP and IL-18 showed associations with poor SRH, and 
for CRP this was true in all three data sets independently of diseases and physical functioning. Yet the empirical 
evidence on interoceptive signalling of humoral processes remains haphazard and for other blood-measured 
substances than inflammatory markers almost non-existent.
In our study, as in many previous ones, SRH showed a strong, robust association with mortality. Poorer SRH 
predicted mortality even after adjusting for chronic conditions in the total sample and in the subsample without 
chronic conditions. Adjusting for biomarkers weakened this association in both situations, which supports our 
initial hypothesis.
We were able to utilize three large population-based data sets from multiple European countries, but, unfor-
tunately, not all biomarkers were available in more than one data set, which would allowed the principles of 
conventional replication studies. For some of the biomarkers investigated the association with SRH had already 
been reported earlier. The strengths of our study included the fact that we had access to a large number of new 
biomarkers; that several of them were available in more than one data set; that we had access to data on chronic 
conditions and physical functioning; and that in one sample it was also possible to investigate mortality. Multi-
morbidity indicated by the number of disease diagnoses is an effective descriptive of health and has prognostic 
 value47–49. In our analysis, the six clinical diagnoses available for analysis in the three study samples were com-
mon and chronic. However, several important diagnostic categories were absent from our analysis, and we had 
no information on disease severity other than physical functioning. Therefore, the data available was not ideal 
to adjust for disease. These are the major limitations of the study. In our exploratory analyses, linear regression 
models were used to provide an easily understandable overview on the associations of SRH, basically an ordi-
nal variable, with biomarkers; this approach is consistent with several earlier studies, and based on observed 
continuity in its association with many other health variables. Further, because of the explorative approach, we 
decided not to construct organ-specific or cluster-based groupings of the biomarkers, and as the role of individual 
biomarkers in connection to SRH is not known, we decided to include all available measures in our analyses 
without selection. The mechanisms linking biomarkers with SRH were also beyond the scope of this study. 
Further studies are needed to shed light on the full pathways between SRH and the biological state of the body.
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In conclusion, our study demonstrated strong and logical associations of SRH with numerous biomarkers 
measured in blood and urine, even independently of chronic diseases and functional status. Poorer SRH was 
associated with worse biomarker levels and vice versa. These biomarkers were descriptive of many different organ 
systems and bodily processes. The findings suggest that SRH has a solid biological basis. Our results also lend 
support to the notion that SRH is a robust, comprehensive but non-specific indicator that can more exhaustively 
capture health-related processes than many conventional measures of health and disease. To verify the potential 
of SRH in research and in clinical practice, multidisciplinary research is needed to explore the mechanisms that 
convey messages from body biology to individuals’ subjective assessments.
Methods
Study populations. In MARK-AGE, questionnaires and interviews were conducted and biological data 
collected between 2008 and 2012 at the following recruiting centres: Hall in Tyrol/Innsbruck (Austria), Namur 
(Belgium), Esslingen (Germany), Athens and surrounding regions (Greece), Bologna (Italy), Warsaw (Poland), 
Tampere (Finland) and Leiden (The Netherlands)50,51. The total number of participants in this analysis was 3,187 
(age range 18–92 years).
CAMB collected questionnaire data and biological samples from 5,335 participants (age range 48–62 years) 
in 2009–2011. This data set comprises participants from three cohort studies: the Metropolit 1953 Danish Male 
Birth Cohort (MP), the Copenhagen Perinatal Cohort (CPC) born in 1959–1961, and the Danish Longitudinal 
Study on Work, Unemployment and Health (DALWUH) born in 1949 or  195952.
Health 2000 is a nationwide survey conducted in 2000–2001 with a randomly selected sample (n = 8,028) of 
the Finnish population aged 30 years or  over53. For this analysis we used a subsample of 6,444 participants (age 
range 30– 99 years) with relevant information.
No human participants were directly involved in the current study and only data was taken for the current 
study.
Measures. SRH was assessed in interviews and questionnaires. In MARK-AGE and CAMB, SRH was 
inquired by asking: “In general, would you say your health is…?”; and in Health 2000 by asking: “Is your pre-
sent state of health…?”. The response options were “poor”, “fair”, “good”, “very good” or “excellent” (CAMB and 
MARK-AGE) and “poor”, “rather poor”, “moderate”, “rather good” or “good” (Health 2000). In linear regression 
models, SRH was used as a continuous variable ranging from 0 to 4, with a higher value referring to poorer SRH. 
For the other analyses, the two poorest SRH categories (poor & fair in MARK-AGE and CAMB; poor & rather 
poor in Health 2000) were combined into one. Then, as an outcome in logistic regression analyses (in Fig. 2), 
SRH was dichotomized as poor versus all other categories. In mortality analysis (Health 2000) SRH was grouped 
into four categories: (1) good, (2) rather good, (3) moderate and (4) poor.
A total of 150 biomarkers measured in blood and urine were available for analysis (full list shown in Supple-
mentary information 1): 134 biomarkers in MARK-AGE, 14 in CAMB, and 28 in Health 2000. All measurements 
were carried out in accordance with relevant guidelines and regulations. Altogether 17 biomarkers were available 
in two or three of the study populations. A few biomarkers were measured with two different but equivalent 
measurements. The proportion of missing biomarker data ranged from 0.05 to 25%. A few biomarkers represent-
ing different biological domains were selected for inclusion in Fig. 2 as examples of previously shown and new 
associations with SRH. For this illustration, biomarker levels were categorized as quartiles.
The indicator of physical functioning came from interviews, questionnaires and hand grip strength meas-
urements. A summary variable for physical functioning was constructed out of three components: (1) ability to 
walk 0.5 mile (in MARK-AGE), 0.25 mile (in CAMB) or 0.5 km (in Health 2000); (2) ability to run 100 m (in 
CAMB and Health 2000) or do vigorous activities such as running, lifting heavy objects, participating in strenu-
ous sports (in MARK-AGE); and (3) hand grip strength (MARK-AGE, CAMB, Health 2000). In each of these 
three components, more points corresponded to poorer functioning. The components of walking and running & 
vigorous activities were scored as 0 = no limitations, 1 = moderate limitations and 2 = highly limited or cannot do 
at all. Hand grip strength was grouped in tertiles (categories 0, 1 and 2). The scores from the three components 
were added together to obtain a sum score of physical functioning, ranging from 0 to 6.
Disease diagnoses, including cardiovascular diseases, hypertension, diabetes, cancer/tumour, respiratory 
diseases and arthritis were obtained from interview and questionnaire data. The variable “number of diseases” 
ranged from 0 to 6 diseases, but in the final analyses it was categorized as 0, 1, 2, 3 or 4 + diseases. In addition, 
subsamples with participants without any of the above mentioned diagnoses were extracted in each data set 
(MARK-AGE n = 1,657; CAMB n = 2,499; Health 2000 n = 2574; characteristics in Supplementary information 
2: Table S3).
Mortality data were only available for the Health 2000 sample. Dates of death were drawn from the National 
Register on Causes of Death maintained by Statistics Finland, and the length of follow-up was 15 years.
Statistical analysis. The association between each individual biomarker and SRH was first explored using 
linear regression analysis in the three independent cross-sectional data sets (MARK-AGE, CAMB and Health 
2000). SRH was the dependent variable, and the models were adjusted for (i) age as a continuous variable and 
gender, and (ii) additionally for the number of diseases and physical functioning. All MARK-AGE analyses were 
adjusted for recruitment centre. The nominal p-value threshold was set at 0.05 for biomarkers that were available 
in two or three data sets (specifically, it was required that the p-value threshold had to be met in all data sets), 
and, to control the multiple testing problem, at Bonferroni-adjusted p-value of 0.05 for biomarkers that were 
available in one data set only. Additionally, logistic regression models were used to analyse the associations of 
12
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6139  | https://doi.org/10.1038/s41598-021-85668-7
www.nature.com/scientificreports/
eight selected biomarkers, categorized as quartiles, with poor SRH, adjusted for age and gender. The results of 
the eight selected biomarkers were visualized as forest plots (Fig. 2).
Next, the association of SRH with all-cause mortality in the Health 2000 data set was analysed using Cox 
proportional hazard modelling (iii). 1) The model was adjusted for (1) age and gender; (2) additionally for 
number of diseases; and (3) furthermore additionally for the biomarkers that were associated with SRH in the 
linear regression analysis (Model ii). The nominal p-value threshold was set at 0.05. These results were visual-
ized as forest plot (Fig. 3).
Finally, we repeated the analyses of the associations between SRH and the biomarkers in all three data sets 
and the mortality analysis in the Health 2000 data in subsamples without disease diagnoses. The criteria for 
statistical significance were the same as in the main analysis.
The data was processed, analysed and visualized using R software (R 3.4.0) and IBM SPSS software version 
24.0 (IBM Corp., Armonk, New York, USA). In each model, participants with missing data for a biomarker, 
mortality, age, gender, SRH, physical functioning or number of diseases were excluded from the analyses.
Ethics approval. Human participants were not directly involved in the current study and only existing data 
was taken for the current analysis. The study was conducted in accordance with the Declaration of Helsinki 
ethical principles and all research participants gave their informed consent to be part of the study. The studies 
(MARK-AGE, CAMB, Health 2000) were approved by the local ethics  committees51–53.
Data availability
The data used in the current study are not publicly available for ethical reasons. However, data are available upon 
request from the Health 2000 survey, MARK-AGE and CAMB for researchers who meet the criteria for access 
to confidential data. Data from the MARK-AGE study are available from the MARK-AGE steering commit-
tee (contact: Alexander Bürkle, alexander.buerkle@uni-konstanz.de). Data from CAMB are available from the 
Copenhagen Aging and Midlife Biobank steering committee (https ://camb.ku.dk/, contact: Rikke Lund, rilu@
sund.ku.dk). Health 2000 data are available from THL on request, subject to the submission of approved study 
proposals and a data transfer agreement (contact: terveys-2000-2011@thl.fi).
Received: 9 February 2020; Accepted: 1 March 2021
References
 1. Jylhä, M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Soc. Sci. Med. 69, 
307–316 (2009).
 2. Idler, E. & Benyamini, Y. Self-rated health and mortality: a review of twenty-seven community studies. J. Health Soc. Behav. 38, 
21–37 (1997).
 3. Jylhä, M., Volpato, S. & Guralnik, J. M. Self-rated health showed a graded association with frequently used biomarkers in a large 
population sample. J. Clin. Epidemiol. 59, 465–471 (2006).
 4. Fried, L. P. et al. Risk factors for 5-year mortality in older adults: the cardiovascular health study. JAMA 279, 585–592 (1998).
 5. Mackenbach, J. P., Simon, J. G., Looman, C. W. & Joung, I. M. Self-assessed health and mortality: could psychosocial factors explain 
the association?. Int. J. Epidemiol. 31, 1162–1168 (2002).
 6. Chen, H., Cohen, P. & Kasen, S. Cohort differences in self-rated health: evidence from a three-decade, community-based, longi-
tudinal study of women. Am. J. Epidemiol. 166, 439–446 (2007).
 7. Park, S., Ahn, J. & Lee, B. K. Self-rated subjective health status is strongly associated with sociodemographic factors, lifestyle, nutri-
ent intakes, and biochemical indices, but not smoking status: KNHANES 2007–2012. J. Korean Med. Sci. 30, 1279–1287 (2015).
 8. Shirom, A., Toker, S., Melamed, S. & Shapira, I. The relationships between self-rated health and serum lipids across time. Int. J. 
Behav. Med. 19, 73–81 (2012).
 9. Tomten, S. E. & Hostmark, A. T. Self-rated health showed a consistent association with serum HDL-cholesterol in the cross-
sectional Oslo Health Study. Int. J. Med. Sci. 4, 278–287 (2007).
 10. Nixon Andreasson, A. et al. Associations between leptin and self-rated health in men and women. Gend. Med. 7, 261–269 (2010).
 11. Unden, A. et al. Inflammatory cytokines, behaviour and age as determinants of self-rated health in women. Clin. Sci. 112, 363 
(2007).
 12. Nakata, A., Takahashi, M., Otsuka, Y. & Swanson, N. G. Is self-rated health associated with blood immune markers in healthy 
individuals?. Int. J. Behav. Med. 17, 234–242 (2010).
 13. Christian, L. M. et al. Poorer self-rated health is associated with elevated inflammatory markers among older adults. Psychoneu-
roendocrinology 36, 1495–1504 (2011).
 14. Tanno, K. et al. Poor self-rated health is significantly associated with elevated C-reactive protein levels in women, but not in men, 
in the Japanese general population. J. Psychosom. Res. 73, 225–231 (2012).
 15. Leshem-Rubinow, E. et al. Self-rated health is associated with elevated C-reactive protein even among apparently healthy individu-
als. Isr. Med. Assoc. J. 17, 213–218 (2015).
 16. Andreasson, A. N. et al. Inflammation and positive affect are associated with subjective health in women of the general population. 
J. Health. Psychol. 18, 311–320 (2013).
 17. Arnberg, F. K., Lekander, M., Morey, J. N. & Segerstrom, S. C. Self-rated health and interleukin-6: longitudinal relationships in 
older adults. Brain Behav. Immun. 54, 226–232 (2016).
 18. Jarczok, M. N. et al. Investigating the associations of self-rated health: heart rate variability is more strongly associated than inflam-
matory and other frequently used biomarkers in a cross sectional occupational sample. PLoS ONE 10, e0117196 (2015).
 19. Rafiq, R. et al. Associations of serum 25-hydroxyvitamin D concentrations with quality of life and self-rated health in an older 
population. J. Clin. Endocrinol. Metab. 99, 3136–3143 (2014).
 20. Tepper, S. et al. Vitamin D status and quality of life in healthy male high-tech employees. Nutrients 8, 366. https ://doi.org/10.3390/
nu806 0366 (2016).
 21. Quadt, L., Critchley, H. D. & Garfinkel, S. N. The neurobiology of interoception in health and disease. Ann. N. Y. Acad. Sci. 1428, 
112–128 (2018).
 22. Dantzer, R., O’Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when 
the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46–56 (2008).
13
Vol.:(0123456789)
Scientific Reports |         (2021) 11:6139  | https://doi.org/10.1038/s41598-021-85668-7
www.nature.com/scientificreports/
 23. Justice, J. N. et al. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the 
TAME Biomarkers Workgroup. Geroscience 40, 419–436 (2018).
 24. Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L. & Carmeliet, G. Vitamin D: metabolism, molecular mechanism of action, 
and pleiotropic effects. Physiol. Rev. 96, 365–408 (2016).
 25. Duggal, N. A. Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions. Biogerontology 19, 
481–496 (2018).
 26. Jääskeläinen, T. et al. Higher serum 25-hydroxyvitamin D concentrations are related to a reduced risk of depression. Br. J. Nutr. 
113, 1418–1426 (2015).
 27. Autier, P., Boniol, M., Pizot, C. & Mullie, P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2, 
76–89 (2014).
 28. Schottker, B. et al. Is vitamin D deficiency a cause of increased morbidity and mortality at older age or simply an indicator of poor 
health?. Eur. J. Epidemiol. 29, 199–210 (2014).
 29. Eisenhauer, B., Natoli, S., Liew, G. & Flood, V. M. Lutein and zeaxanthin-food sources, bioavailability and dietary variety in age-
related macular degeneration protection. Nutrients 9, 120. https ://doi.org/10.3390/nu902 0120.eColl ectio n2017 Feb (2017).
 30. Lima, V. C., Rosen, R. B. & Farah, M. Macular pigment in retinal health and disease. Int. J. Retina Vitreous https ://doi.org/10.1186/
s4094 2-016-0044-9 (2016).
 31. Feng, M., Rached, F., Kontush, A. & Chapman, M. J. Impact of lipoproteins on atherobiology: emerging insights. Cardiol. Clin. 36, 
193–201 (2018).
 32. Ziegler, A., Zangemeister-Wittke, U. & Stahel, R. A. Circulating DNA: a new diagnostic gold mine?. Cancer Treat. Rev. 28, 255–271 
(2002).
 33. Saukkonen, K. et al. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin. Chem. 54, 1000–1007 
(2008).
 34. Jylhävä, J. et al. Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey. Atherosclerosis 
233, 268–271 (2014).
 35. Gogenur, M., Burcharth, J. & Gogenur, I. The role of total cell-free DNA in predicting outcomes among trauma patients in the 
intensive care unit: a systematic review. Crit. Care 21, 14. https ://doi.org/10.1186/s1305 4-016-1578-9 (2017).
 36. Fatouros, I. G. et al. Cell-free plasma DNA as a novel marker of aseptic inflammation severity related to exercise overtraining. 
Clin. Chem. 52, 1820–1824 (2006).
 37. Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer. 11, 426–437 
(2011).
 38. Dalle-Donne, I., Rossi, R., Giustarini, D., Milzani, A. & Colombo, R. Protein carbonyl groups as biomarkers of oxidative stress. 
Clin. Chim. Acta 329, 23–38 (2003).
 39. Manderbacka, K., Lundberg, O. & Martikainen, P. Do risk factors and health behaviours contribute to self-ratings of health?. Soc. 
Sci. Med. 48, 1713–1720 (1999).
 40. Kaplan, G. A. & Camacho, T. Perceived health and mortality: a nine-year follow-up of the human population laboratory cohort. 
Am. J. Epidemiol. 117, 292–304 (1983).
 41. Stenback, A. Physical health and physical disease as objective fact and subjective experience. Arch Gen Psychiatry 11, 290–301 
(1964).
 42. Craig, A. D. Interoception: the sense of the physiological condition of the body. Curr. Opin. Neurobiol. 13, 500–505 (2003).
 43. Cameron, O. G. Interoception: the inside story—a model for psychosomatic processes. Psychosom. Med. 63, 697–710 (2001).
 44. Van den Bergh, O., Witthoft, M., Petersen, S. & Brown, R. J. Symptoms and the body: taking the inferential leap. Neurosci. Biobehav. 
Rev. 74, 185–203 (2017).
 45. Molarius, A. & Janson, S. Self-rated health, chronic diseases, and symptoms among middle-aged and elderly men and women. J. 
Clin. Epidemiol. 55, 364–370 (2002).
 46. Moreh, E., Jacobs, J. M. & Stessman, J. Fatigue, function, and mortality in older adults. J. Gerontol. A Biol. Sci. Med. Sci. 65, 887–895 
(2010).
 47. Hernández, B., Reilly, R. B. & Kenny, R. A. Investigation of multimorbidity and prevalent disease combinations in older Irish adults 
using network analysis and association rules. Sci. Rep. 9, 14567 (2019).
 48. Halonen, P., Raitanen, J., Jämsen, E., Enroth, L. & Jylhä, M. Chronic conditions and multimorbidity in population aged 90 years 
and over: associations with mortality and long-term care admission. Age Ageing 48, 564–570 (2019).
 49. Willadsen, T. G. et al. Multimorbidity and mortality: A 15-year longitudinal registry-based nationwide Danish population study. 
J. Comorb https ://doi.org/10.1177/22350 42X18 80406 3 (2018).
 50. Bürkle, A. et al. MARK-AGE biomarkers of ageing. Mech. Ageing Dev. 151, 2–12 (2015).
 51. Moreno-Villanueva, M. et al. MARK-AGE standard operating procedures (SOPs): a successful effort. Mech. Ageing Dev. 151, 18–25 
(2015).
 52. Lund, R. et al. Cohort profile: the Copenhagen Aging and Midlife Biobank (CAMB). Int. J. Epidemiol. 45, 1044–1053 (2016).
 53. Heistaro, S. Methodology Report: Health 2000 Survey. Publications of the National Public Health Institute. B26/2008. Helsinki, 
Finland (2008).
Acknowledgements
The authors extend their thanks to all participants from the different study centres in MARK-AGE, CAMB and 
Health 2000. They also acknowledge the financial support provided by the European Commission through the 
FP7 large-scale integrating project “European Study to Establish Biomarkers of Human Ageing” (MARK-AGE; 
grant agreement No.: 200880). The Copenhagen Aging and Midlife Biobank was funded by generous grants from 
the VELUX FOUNDATION (VELUX 26145 and 31539), and this manuscript was prepared in collaboration with 
members of the CAMB steering committee. The members of the CAMB steering committee and those responsible 
for the collection of historical data are listed at http://www.camb.ku.dk/. Drude Molbo from the University of 
Copenhagen is thanked for data delivery services. Furthermore, thanks are extended to all the working groups 
involved in the Health 2000 data survey, particularly to Jorma Sundvall, Britt-Marie Loo, Tuija Jääskeläinen and 
Harri Rissanen for data delivery services. The persons responsible in the Health 2000 survey project groups 
are listed at https ://thl.fi/fi/tutki mus-ja-kehit tamin en/tutki mukse t-ja-hankk eet/terve ys-2000-2011. The Health 
2000 Survey was funded by the National Institute for Health and Welfare (THL), the Finnish Centre for Pen-
sions (ETK), the Social Insurance Institution of Finland (KELA), the Local Government Pensions Institution 
(KEVA) and other organizations listed on the survey website. This analysis was supported by the Signe and Ane 
Gyllenberg Foundation, Academy of Finland funding for the Centre of Excellence in Research on Ageing and 
Care (CoEAgeCare), and Competitive State Research Financing of the Expert Responsibility area of Tampere 
University Hospital and to the City of Tampere to MJ.
14
Vol:.(1234567890)
Scientific Reports |         (2021) 11:6139  | https://doi.org/10.1038/s41598-021-85668-7
www.nature.com/scientificreports/
Author contributions
M.J. conceived of the study in consultation with L.K. L.K. conducted the analyses, and the text was written by 
L.K. and M.J. All other authors, J.R., J.J., A.B., M.M.-V., J.B., O.T., B.G.-L., M.M., A.B., F.P., S.C., E.S.G., E.S., D.G., 
E.H.J.M.J., M.E.T.D., M.S., W.S., D.W., T.G., N.B., A.S., M.C., C.F., P.E.S., D.C.S.T., C.L., S.K., H.B., Å.M.H., R.L., 
and M.H. made additional analysis suggestions and provided text/references on specific sections. All authors 
contributed to the text of the manuscript and reviewed the final submission.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https ://doi.
org/10.1038/s4159 8-021-85668 -7.
Correspondence and requests for materials should be addressed to M.J.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2021
